1. Search Result
Search Result
Results for "

CRF

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

37

Peptides

1

Natural
Products

32

Recombinant Proteins

1

Antibodies

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1297

    CRFR Neurological Disease
    CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .
    <em>CRF</em>(6-33)(human)
  • HY-P1533A

    Corticotropin Releasing Factor bovine TFA

    CRFR Inflammation/Immunology Endocrinology
    CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ 125I-Tyr]ovine CRF with a Ki of 3.52 nM .
    <em>CRF</em>, bovine TFA
  • HY-P1297A

    CRFR Neurological Disease
    CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .
    <em>CRF</em>(6-33)(human) TFA
  • HY-P1533

    Corticotropin Releasing Factor bovine

    CRFR Inflammation/Immunology Endocrinology
    CRF, bovine is a potent agonist of CRF receptor, and displaces [ 125I-Tyr]ovine CRF with a Ki of 3.52 nM.
    <em>CRF</em>, bovine
  • HY-156522

    CFTR Endocrinology
    CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) .
    <em>CRF</em>1 receptor antagonist-1
  • HY-P1294

    CRFR Neurological Disease
    α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC50 of 140 nM .
    α-Helical <em>CRF</em>(9-41)
  • HY-12339

    CRFR Endocrinology
    NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.
    NVS-<em>CRF</em>38
  • HY-P1294A

    CRFR Neurological Disease
    α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC50 of 140 nM .
    α-Helical <em>CRF</em>(9-41) TFA
  • HY-P4542

    CRFR Endocrinology
    (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a CRF antagonist. (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) prevents the IL-1a induced Luteinizing hormone (LH) inhibition .
    (D-Phe12,Nle21,38,α-Me-Leu37)-<em>CRF</em> (12-41) (human, rat)
  • HY-P4012

    Vasopressin Receptor Endocrinology
    [Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .
    [Asu1,6-Arg8]Vasopressin
  • HY-P3683

    CRFR Endocrinology
    a-Helical Corticotropin Releasing Factor (12-41) is a 30 amino acids long, α-helical analogue of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH). a-Helical Corticotropin Releasing Factor (12-41) would suppress the stimulatory effect .
    a-Helical Corticotropin Releasing Factor (12-41)
  • HY-P3684

    CRFR Endocrinology
    [DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat
  • HY-P1107

    aSvg-30

    CRFR Neurological Disease
    Antisauvagine-30 (aSvg-30) is a potent, competitive and selective CRF2 receptor antagonist with Kd values of 1.4 nM and 153.6 nM for mouse CRF and rat CRF1 receptors, respectively .
    Antisauvagine-30
  • HY-14875

    GSK561679

    CRFR Neurological Disease Endocrinology
    Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.
    Verucerfont
  • HY-P1108

    CFTR Others
    Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .
    Astressin 2B
  • HY-P1108A

    CFTR Others
    Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .
    Astressin 2B TFA
  • HY-P1106

    CRFR Cardiovascular Disease
    K41498 is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF, CRF and CRF1 receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF- and hCRF-expressing cells. K41498 can be used for hypotension study .
    K41498
  • HY-P1106A

    CFTR Cardiovascular Disease
    K41498 TFA is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF, CRF and CRF1 receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF- and hCRF-expressing cells. K41498 TFA can be used for hypotension study .
    K41498 TFA
  • HY-P1542

    Catostomus urotensin I

    CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF and mCRF receptors, respectively .
    Urotensin I
  • HY-P1542B

    Catostomus urotensin I TFA

    CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF and mCRF receptors, respectively .
    Urotensin I TFA
  • HY-P1296

    Urocortin (Rattus norvegicus); Rat urocortin

    CRFR Neurological Disease Endocrinology
    Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF and mouse CRF, respectively .
    Urocortin, rat
  • HY-P1296A

    Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA

    CRFR Neurological Disease Endocrinology
    Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF and mouse CRF, respectively .
    Urocortin, rat TFA
  • HY-12127

    BMS-562086

    CRFR Neurological Disease Endocrinology
    Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.
    Pexacerfont
  • HY-P1858

    CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
    Urocortin III, mouse
  • HY-P1858A

    CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
    Urocortin III, mouse TFA
  • HY-P1752

    CRFR Metabolic Disease Endocrinology
    Urocortin II (human) is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. For investigating the role of the CRF (2) receptor in ingestive behavior .
    Urocortin II, human
  • HY-P1752A

    CRFR Metabolic Disease Endocrinology
    Urocortin II, human (TFA) is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. For investigating the role of the CRF (2) receptor in ingestive behavior .
    Urocortin II, human TFA
  • HY-P3597

    CFTR Others
    Urocortin III (mouse) (free acid) is a selective CRF2 receptor agonist (with high affinity for the CRF2 receptor). Urocortin III (mouse) (free acid) significantly inhibits gastric emptying without modifying colonic transit .
    Urocortin III (mouse) (free acid)
  • HY-110056

    CRFR Neurological Disease
    NBI 35965 hydrochloride is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects .
    NBI 35965 hydrochloride
  • HY-103378

    CRFR Neurological Disease
    NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects .
    NBI 35965 methanesulfonate
  • HY-14129

    CRFR Neurological Disease Endocrinology
    CP 316311 is a potent and selective CRF1 receptor antagonist with an IC50 value of 6.8 nM.
    CP 316311
  • HY-14367

    GW876008

    CRFR Neurological Disease Endocrinology
    Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM.
    Emicerfont
  • HY-P3959

    CRFR Endocrinology
    (Tyr0)-Urocortin, rat is a high-affinity agonist of corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2). (Tyr0)-Urocortin, rat shows inhibitory binding constants (Ki) of 1-2 nM .
    (Tyr0)-Urocortin, rat
  • HY-14132

    CRFR Neurological Disease
    BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM) .
    BMS-665053
  • HY-P3019

    CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with Ki values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .
    Urocortin III (human)
  • HY-14130

    CRFR Neurological Disease Endocrinology
    CP 376395 is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .
    CP 376395
  • HY-103379

    CRFR Neurological Disease Endocrinology
    CP 376395 hydrochloride is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .
    CP 376395 hydrochloride
  • HY-103376

    CRFR Neurological Disease
    NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM .
    NBI-27914 hydrochloride
  • HY-135542

    CRFR Others
    NBI-27914 is a potent and selective antagonist of CRFR1. The CRF receptors, CRFR1 and CRFR2, are members of the G protein-coupled receptor superfamily .
    NBI-27914
  • HY-P2287

    CRFR Neurological Disease
    Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC50 of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model .
    Cortagine
  • HY-P2847

    CRFR Metabolic Disease Endocrinology
    Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with Ki values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca 2+/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .
    Urocortin II, mouse
  • HY-14127
    R121919
    1 Publications Verification

    NBI30775

    CRFR Neurological Disease Endocrinology
    R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats .
    R121919
  • HY-14225

    CRFR Cytochrome P450 Neurological Disease
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer .
    BMS-764459
  • HY-115645

    NBI30775 hydrochloride

    CRFR Neurological Disease Metabolic Disease
    R121919 (NBI30775) hydrochloride is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 hydrochloride has antidepressant and anxiolytic effects. R121919 hydrochloride alleviates defensive withdrawal in rats .
    R121919 hydrochloride
  • HY-P1295

    Urocortin (human); Human urocortin; Human urocortin 1; Human urocortin I

    CRFR Neurological Disease Endocrinology
    Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous CRF2 receptor, with Kis of 0.4, 0.3, and 0.5 nM for hCRF1, rCRF and mCRF, respectively.
    Urocortin, human
  • HY-P3685

    CRFR Endocrinology
    [Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .
    [Met(O)21] Corticotropin Releasing Factor, ovine
  • HY-P3169

    CRFR Inflammation/Immunology
    α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo .
    a-Helical Corticotropin Releasing Factor (9-41)
  • HY-P1298

    CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands .
    Sauvagine
  • HY-108295

    CXB-722

    GABA Receptor Neurological Disease
    Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain .
    Pivagabine
  • HY-P3785

    PKA Neurological Disease
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors .
    PKI(5-22)amide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: